← Back to Screener
MIRA Pharmaceuticals, Inc. Common Stock (MIRA)
Price$1.12
Favorite Metrics
Price vs S&P 500 (26W)-24.62%
Price vs S&P 500 (4W)5.72%
Market Capitalization$44.54M
All Metrics
Book Value / Share (Quarterly)$0.25
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.11
Price vs S&P 500 (YTD)-33.94%
EPS (TTM)$-0.40
10-Day Avg Trading Volume0.12M
EPS Excl Extra (TTM)$-0.40
EPS (Annual)$-0.44
ROI (Annual)-100.49%
Cash / Share (Quarterly)$0.26
ROA (Last FY)-94.13%
EBITD / Share (TTM)$-0.45
Cash Flow / Share (Annual)$-0.11
P/B Ratio4.29x
P/B Ratio (Quarterly)6.08x
Net Income / Employee (Annual)$-3
Net Interest Coverage (TTM)-2.47x
ROA (TTM)-198.95%
EPS Incl Extra (Annual)$-0.44
Current Ratio (Annual)15.75x
Quick Ratio (Quarterly)15.71x
3-Month Avg Trading Volume0.18M
52-Week Price Return-0.93%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.55
52-Week High$2.45
EPS Excl Extra (Annual)$-0.44
26-Week Price Return-15.87%
Quick Ratio (Annual)15.71x
13-Week Price Return-28.38%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)15.75x
Enterprise Value$38.197
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.26
3-Month Return Std Dev76.24%
Net Income / Employee (TTM)$-3
ROE (Last FY)-100.49%
Net Interest Coverage (Annual)-36.85x
EPS Basic Excl Extra (Annual)$-0.44
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.40
ROI (TTM)-210.91%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$-0.04
Price vs S&P 500 (52W)-36.03%
Year-to-Date Return-29.80%
5-Day Price Return2.91%
EPS Normalized (Annual)$-0.44
ROA (5Y Avg)-298.63%
Month-to-Date Return-0.93%
EBITD / Share (Annual)$-0.44
EPS Basic Excl Extra (TTM)$-0.40
P/TBV (Quarterly)5.96x
P/B Ratio (Annual)6.08x
Book Value / Share (Annual)$0.25
Price vs S&P 500 (13W)-31.24%
Beta1.78x
Revenue / Share (TTM)$0.00
ROE (TTM)-210.91%
52-Week Low$0.83
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
MIRAMIRA Pharmaceuticals, Inc. Common Stock | — | — | — | — | $1.12 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Mira Pharmaceuticals is a pre-clinical-stage pharmaceutical company developing treatments for neurologic and neuropsychiatric disorders. The company's lead program, MIRA-55, is an oral cannabinoid candidate in development for anxiety and cognitive decline associated with early-stage dementia.